Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361949968> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4361949968 abstract "<div>Abstract<p><b>Purpose:</b> This multicenter randomized trial was designed to evaluate whether melanoma helper peptides augment cytotoxic T lymphocyte (CTL) responses to a melanoma vaccine and improve clinical outcome in patients with advanced melanoma.</p><p><b>Experimental Design:</b> One hundred seventy-five patients with measurable stage IV melanoma were enrolled into 4 treatment groups, vaccinated with 12 MHC class I-restricted melanoma peptides to stimulate CTL (12MP, group A), plus a tetanus peptide (group B), or a mixture of 6 melanoma helper peptides (6MHP, group C) to stimulate helper T lymphocytes (HTL), or with 6 melanoma helper peptide (6MHP) alone (group D), in incomplete Freund's adjuvant plus granulocyte macrophage colony-stimulating factor. CTL responses were assessed using an <i>in vitro</i>-stimulated IFN-γ ELIspot assay, and HTL responses were assessed using a proliferation assay.</p><p><b>Results:</b> In groups A to D, respectively, CTL response rates to 12 melanoma peptides were 43%, 47%, 28%, and 5%, and HTL response rates to 6MHP were in 3%, 0%, 40%, and 41%. Best clinical response was partial response in 7 of 148 evaluable patients (4.7%) without significant difference among study arms. Median overall survival (OS) was 11.8 months. Immune response to 6 MHP was significantly associated with both clinical response (<i>P</i> = 0.036) and OS (<i>P</i> = 0.004).</p><p><b>Conclusion:</b> Each vaccine regimen was immunogenic, but MHPs did not augment CTL responses to 12 melanoma peptides. The association of survival and immune response to 6MHP supports further investigation of helper peptide vaccines. For patients with advanced melanoma, multipeptide vaccines should be studied in combination with other potentially synergistic active therapies. <i>Clin Cancer Res; 19(15); 4228–38. ©2013 AACR</i>.</p></div>" @default.
- W4361949968 created "2023-04-05" @default.
- W4361949968 creator A5007239425 @default.
- W4361949968 creator A5009744576 @default.
- W4361949968 creator A5019487042 @default.
- W4361949968 creator A5027983821 @default.
- W4361949968 creator A5049294342 @default.
- W4361949968 creator A5050172772 @default.
- W4361949968 creator A5069447264 @default.
- W4361949968 creator A5074182063 @default.
- W4361949968 creator A5090865977 @default.
- W4361949968 date "2023-03-31" @default.
- W4361949968 modified "2023-10-16" @default.
- W4361949968 title "Data from A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)" @default.
- W4361949968 doi "https://doi.org/10.1158/1078-0432.c.6520512.v1" @default.
- W4361949968 hasPublicationYear "2023" @default.
- W4361949968 type Work @default.
- W4361949968 citedByCount "0" @default.
- W4361949968 crossrefType "posted-content" @default.
- W4361949968 hasAuthorship W4361949968A5007239425 @default.
- W4361949968 hasAuthorship W4361949968A5009744576 @default.
- W4361949968 hasAuthorship W4361949968A5019487042 @default.
- W4361949968 hasAuthorship W4361949968A5027983821 @default.
- W4361949968 hasAuthorship W4361949968A5049294342 @default.
- W4361949968 hasAuthorship W4361949968A5050172772 @default.
- W4361949968 hasAuthorship W4361949968A5069447264 @default.
- W4361949968 hasAuthorship W4361949968A5074182063 @default.
- W4361949968 hasAuthorship W4361949968A5090865977 @default.
- W4361949968 hasBestOaLocation W43619499682 @default.
- W4361949968 hasConcept C126322002 @default.
- W4361949968 hasConcept C147483822 @default.
- W4361949968 hasConcept C147969180 @default.
- W4361949968 hasConcept C154317977 @default.
- W4361949968 hasConcept C167672396 @default.
- W4361949968 hasConcept C195616568 @default.
- W4361949968 hasConcept C202751555 @default.
- W4361949968 hasConcept C203014093 @default.
- W4361949968 hasConcept C2776789287 @default.
- W4361949968 hasConcept C2777658100 @default.
- W4361949968 hasConcept C2777701055 @default.
- W4361949968 hasConcept C2779053233 @default.
- W4361949968 hasConcept C502942594 @default.
- W4361949968 hasConcept C55493867 @default.
- W4361949968 hasConcept C71924100 @default.
- W4361949968 hasConcept C86803240 @default.
- W4361949968 hasConcept C8891405 @default.
- W4361949968 hasConceptScore W4361949968C126322002 @default.
- W4361949968 hasConceptScore W4361949968C147483822 @default.
- W4361949968 hasConceptScore W4361949968C147969180 @default.
- W4361949968 hasConceptScore W4361949968C154317977 @default.
- W4361949968 hasConceptScore W4361949968C167672396 @default.
- W4361949968 hasConceptScore W4361949968C195616568 @default.
- W4361949968 hasConceptScore W4361949968C202751555 @default.
- W4361949968 hasConceptScore W4361949968C203014093 @default.
- W4361949968 hasConceptScore W4361949968C2776789287 @default.
- W4361949968 hasConceptScore W4361949968C2777658100 @default.
- W4361949968 hasConceptScore W4361949968C2777701055 @default.
- W4361949968 hasConceptScore W4361949968C2779053233 @default.
- W4361949968 hasConceptScore W4361949968C502942594 @default.
- W4361949968 hasConceptScore W4361949968C55493867 @default.
- W4361949968 hasConceptScore W4361949968C71924100 @default.
- W4361949968 hasConceptScore W4361949968C86803240 @default.
- W4361949968 hasConceptScore W4361949968C8891405 @default.
- W4361949968 hasLocation W43619499681 @default.
- W4361949968 hasLocation W43619499682 @default.
- W4361949968 hasOpenAccess W4361949968 @default.
- W4361949968 hasPrimaryLocation W43619499681 @default.
- W4361949968 hasRelatedWork W1968442017 @default.
- W4361949968 hasRelatedWork W1980416103 @default.
- W4361949968 hasRelatedWork W2015969707 @default.
- W4361949968 hasRelatedWork W2018916009 @default.
- W4361949968 hasRelatedWork W2054101033 @default.
- W4361949968 hasRelatedWork W2058428031 @default.
- W4361949968 hasRelatedWork W2166919567 @default.
- W4361949968 hasRelatedWork W2417323613 @default.
- W4361949968 hasRelatedWork W3030234753 @default.
- W4361949968 hasRelatedWork W3144087197 @default.
- W4361949968 isParatext "false" @default.
- W4361949968 isRetracted "false" @default.
- W4361949968 workType "article" @default.